Floatz logo

il-15 enhanced engineered nk cells

Childhood Solid Tumor

Hospital Infantil Universitario Niño Jesús, Madrid, SpainCell therapyPhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

33 Active assets in the Childhood Solid Tumor cohort.

Asset / SponsorPhaseRating
(+)-VINCRISTINE
Tianjin Medical University Cancer Institute and Hospital
Phase 2BB
Cyclophosphamide
St. Jude Children's Research Hospital
Phase 2BB
Nivolumab
Australian & New Zealand Children's Haematology/Oncology Group
Phase 2B
OTL-38
Mayo Clinic
Phase 3B
Irinotecan
Australian & New Zealand Children's Haematology/Oncology Group
Phase 1/2B

View all 50 →

Same molecule, other indications

il-15 enhanced engineered nk cells is also rated in:

lymphoid system disorderDormant
CC
Indicative ·
43 / 100
View asset →
pancreatic neoplasmDormant
CC
Indicative ·
40 / 100
View asset →
Hodgkins lymphomaDormant
C
Indicative ·
37 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →